January 9, 2020 – Imagine living with unwanted sexual arousals, occurring unexpectedly and repeatedly, unrelated to any sexual desire or pleasure. That’s the situation for women with a rare and disabling condition called persistent genital arousal disorder (PGAD), according to a case series in PAIN Reports®, the official open-access journal of the International Association for the Study of Pain (IASP). The journal is published in the Lippincott portfolio by Wolters Kluwer.
The study provides new insights into the experience of women with PGAD, and strongly suggests that it should be evaluated and treated as a neurological condition. “This report associates PGAD with disorders and lesions of the lower spinal cord, roots, and nerves that control sexual arousal and orgasm,” according to the paper by Saurabh Sharma, MD, of McLean Hospital and Harvard Medical School and colleagues.
Neurological Evaluation Provides Clues to Causes and Effective Treatments
The researchers describe ten women evaluated by university medical center neurologists for PGAD: a rare condition characterized by “out-of-context sexual arousal and/or orgasm.” Most of the women had daily episodes of sexual arousal, lasting from minutes to hours. Some had longer, near-continuous episodes lasting for days or even years.
Arousals could be triggered by a wide range of factors, or by nothing at all. Nearly all patients tried masturbation to end the episodes; though not pleasurable, this provided temporary respite for some. “Chronic PGAD always terminated sexual relations,” Dr. Sharma and coauthors wrote. “Every patient reported that PGAD caused new or worse anxiety or depression.”
Psychiatric treatments for PGAD were “universally ineffective.” In the oldest patient, this included many psychiatric hospitalizations and electroconvulsive therapy sessions. Medications, injections, and nerve blocks were also ineffective, and sometimes made symptoms worse.
In contrast, neurological evaluation helped identify associated factors and possible causes of PGAD. All but one of the women had “co-localizing somatosensory symptoms,” such as pelvic, buttock, or leg pain. Neurological tests provided additional information in several patients, with findings including spinal nerve root lesions, nerve conduction abnormalities, and sensory nerve disorders.
In several cases, neurological evaluation led to effective neurological treatments. One patient was cured by surgery to remove nerve cysts in the sacral region (lower spine and pelvis). One patient got lasting relief from tapering use of an antidepressant drug linked to the onset of symptoms. In another patient, IV immune globulin led to improvement in PGAD and other neurological symptoms.
Although the true prevalence of PGAD is unknown, it appears to occur mainly in women – only a handful of cases have been reported in men. “Women’s complaints of inappropriate arousal are typically attributed (by predominantly male evaluators) to psychopathology or misinterpreted as beneficial,” according to the authors. They note that there are thousands of posts on Internet forums, usually by women, seeking information about PGAD or similar symptoms.
Given the locations, cause, and accompanying neurological signs and symptoms, Dr. Sharma and coauthors write, “[W]e propose that at least some PGAD cases arise from lesions affecting the sacral [pelvic] sensory networks that transmit sexual arousal.” They suggest that PGAD should be regarded as “a disorder of special sensation akin to neuropathic pain and itch.”
The article includes suggestions for neurological evaluation and treatment for patients affected by this rare “special sense neuropathy.” Dr. Sharma and colleagues conclude: “Our findings will have clinical implications if confirmed, because most PGAD patients now linger medically undiagnosed and untreated.”
###
Click here to read “Persistent genital arousal disorder: a special sense neuropathy.”
DOI: 10.1097/PR9.0000000000000801
About PAIN Reports
PAIN Reports is an official publication of the IASP. An open access multidisciplinary journal, PAIN Reports promotes a global, rapid, and readily accessible forum that advances clinical, applied, and basic research on pain. The online journal publishes full-length articles as well as brief reports, reviews, meta-analyses, meeting proceedings, and selected case reports. PAIN Reports gives special attention to submissions reporting the results of enterprising and high-risk research and pilot studies as well as locally developed clinical guidelines from scientists and clinicians in developing countries. IASP also publishes the journal PAIN.
About the International Association for the Study of Pain
IASP is the leading professional forum for science, practice, and education in the field of pain. Membership is open to all professionals involved in research, diagnosis, or treatment of pain. IASP has more than 7,000 members in 133 countries, 90 national chapters, and 20 special interest groups (SIGs). IASP brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain and translate that knowledge into improved pain relief worldwide.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit //healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit //www.